EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Safety and feasibility of early discharge after transcatheter aortic valve implantation with ACURATE Neo—the POLESTAR trial

Joris F Ooms, Kristoff Cornelis, Harindra C Wijeysundera, Bert Vandeloo, Jan Van Der Heyden, Jan Kovac, David Wood, Albert Chan, Joanna Wykrzykowska, Liesbeth Rosseel, Michael Cunnington, Frank van der Kley und 4 weitere

Clinical Research in Cardiology · 2025

DOI: 10.1007/s00392-024-02436-z ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Research in Cardiology, 2025. Verfasst von Joris F Ooms und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Patient Discharge, Heart Valve Prosthesis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boston Scientific Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Transcatheter aortic valve implantation (TAVI) serves a growing range of patients with severe aortic stenosis (AS). TAVI has evolved to a streamlined procedure minimizing length of hospital stay.

Aims

To evaluate the safety and efficacy of an early discharge (ED) strategy after TAVI.

Methods

We performed an international, multi-center, prospective observational single-arm study in AS patients undergoing TAVI with the ACURATE valve platform. Eligibility for ED was assessed prior to TAVI and based on prespecified selection criteria. Discharge ≤ 48 h was defined as ED. Primary Valve Academic Research Consortium (VARC)-3-defined 30-day safety and efficacy composite endpoints were landmarked at 48 h and compared between ED and non-ED groups.

Results

A total of 252 patients were included. The median age was 82 [25th–75th percentile, 78–85] years and the median Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) score was 2.2% [25th–75th percentile, 1.6–3.3]. ED and non-ED were achieved in 173 (69%) and 79 (31%) patients respectively. Monitoring for conduction disturbances was the principal reason for non-ED (33%). Overall, at 30 days, all-cause mortality was 1%, new permanent pacemaker rate was 4%, and valve- or procedure-related rehospitalization was 4%. There was no difference in the primary safety and efficacy endpoint between the ED and non-ED cohorts (OR 0.84 [25th–75th percentile, 0.31–2.26], p = 0.73, and OR 0.97 [25th–75th percentile, 0.46–2.06], p = 0.94). The need for rehospitalization was similarly low for ED and non-ED groups.

Conclusion

Early discharge after TAVI with the ACURATE valve is safe and feasible in selected patients. Rhythm monitoring and extended clinical observation protracted hospital stay. Graphical Abstract Safety and feasibility of early discharge after transcatheter aortic valve implantation with ACURATE Neo, an international multi-center, prospective observational single-arm study. OR, odds ratio (95% confidence interval); VARC, Valve Academic Research Consortium

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcatheter Aortic Valve ReplacementAortic Valve StenosisPatient DischargeHeart Valve ProsthesisAortic ValveHumansMaleFemaleAged, 80 and overProspective StudiesFeasibility StudiesAgedTime FactorsLength of StayTreatment OutcomeFollow-Up StudiesPostoperative ComplicationsProsthesis DesignSeverity of Illness Index

Stichwörter der Autor:innen

Early dischargeSelf-expanding valveTAVI

Autor:innen und Institutionen

  • Department of Interventional Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • AZ Maria Middelares, Ghent, Belgium.
  • Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • University Hospital Brussels, Brussels, Belgium.
  • Sint Jan Hospital, Brugge, Belgium.
  • University Hospitals Leicester NHS Trust, Leicester, UK.

Förderung

  • Boston Scientific Corporation

Zitieren

APA

Ooms, J. F., Cornelis, K., Wijeysundera, H. C., Vandeloo, B., Van Der Heyden, J., Kovac, J., Wood, D., Chan, A., Wykrzykowska, J., Rosseel, L., Cunnington, M., van der Kley, F., Rensing, B., Voskuil, M., Hildick-Smith, D., & Van Mieghem, N. M. (2025). Safety and feasibility of early discharge after transcatheter aortic valve implantation with ACURATE Neo—the POLESTAR trial. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-024-02436-z

Vancouver

Ooms JF, Cornelis K, Wijeysundera HC, Vandeloo B, Van Der Heyden J, Kovac J, et al. Safety and feasibility of early discharge after transcatheter aortic valve implantation with ACURATE Neo—the POLESTAR trial. Clinical Research in Cardiology. 2025. doi:10.1007/s00392-024-02436-z

BibTeX
@article{Ooms2025,
  author = {Ooms, Joris F and Cornelis, Kristoff and Wijeysundera, Harindra C and Vandeloo, Bert and Van Der Heyden, Jan and Kovac, Jan and Wood, David and Chan, Albert and Wykrzykowska, Joanna and Rosseel, Liesbeth and Cunnington, Michael and van der Kley, Frank and Rensing, Benno and Voskuil, Michiel and Hildick-Smith, David and Van Mieghem, Nicolas M},
  title = {Safety and feasibility of early discharge after transcatheter aortic valve implantation with ACURATE Neo—the POLESTAR trial},
  journal = {Clinical Research in Cardiology},
  year = {2025},
  doi = {10.1007/s00392-024-02436-z}
}
Kostenlos starten →